Syncom Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Syncom Pharmaceuticals's estimated annual revenue is currently $4.4M per year.
- Syncom Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Syncom Pharmaceuticals has 22 Employees.
- Syncom Pharmaceuticals grew their employee count by 5% last year.
Syncom Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President | Reveal Email/Phone |
Syncom Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Syncom Pharmaceuticals?
Established in 1985, Syncom has more than 25 years experience providing contract-sales services to life sciences manufacturers, developers and marketers. Headquartered in a spacious office complex in Fairfield, New Jersey, within close proximity to an immense concentration of biotech and pharmaceutical companies, Syncom has easy access to a myriad of industry resources and contacts.
keywords:N/A
N/A
Total Funding
22
Number of Employees
$4.4M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Syncom Pharmaceuticals News
... Gufic BioSciences Ltd (up 5.39%), Suven Pharmaceuticals Ltd (up ... 3.35%),Torrent Pharmaceuticals Ltd (up 3.22%),Syncom Formulations...
Reported Standalone quarterly numbers for Syncom Formulations are: Net Sales at Rs 57.23 crore in December 2021 down 32.01% from Rs. 84.17 crore...
Other Companies in Fairfield
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.2M | 22 | 5% | N/A |
#2 | $2.2M | 22 | 5% | N/A |
#3 | $4.1M | 22 | -37% | N/A |
#4 | $4.2M | 22 | 0% | N/A |
#5 | $2.3M | 23 | N/A | N/A |